EN DE

PeopleBio Inc (304840) Fair Value & Analysis

Healthcare · KR · Market cap 21.3B KRW

PI PeopleBio Inc 304840 · KQ
Price from Jul 31, 2026561.00 KRW
Fair Value504.98 KRW
Upside-10.0%
Quality22/100
Watch PeopleBio Inc for free, get notified when fair value or trend changes. Watch for free

Risks

!Mixed Growth
!Loss-making · -94.7% net margin
!Low debt · negative free cash flow
!Mixed vs. peers (3/6)
Mixed Growth
Loss-making · -94.7% net margin
Low debt · negative free cash flow
Mixed vs. peers (3/6)
Narrow moat 5/100
Evidence: Low Range 376.85 KRW – 753.70 KRW Share as image

Fair value as of: Aug 13, 2026

From 1 valuation models · updated 7 days ago

Fair value updated Aug 13, 2026, revised from 905.70 KRW to 504.98 KRW (−44.2%) since Jul 22, 2026. Share price −31.0% over the past month.

Below-average quality, currently priced close to our fair value.

Fair value for all 35,000+ stocks, review alerts and the diversification check: 14 days of Pro free, no card.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • A fairly wide model range (376.85 KRW to 753.70 KRW) leaves room in how you read the outcome.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

19,887 KRW 561.00 KRW Fair Value 504.98 KRW Mar 2021 Jul 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 561.00 KRW – 19,887 KRW · fair‑value band 376.85 KRW – 753.70 KRW · the 561.00 KRW price screens above the 504.98 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

PeopleBio Inc (304840) currently trades at 561.00 KRW, while our model-based Fair Value estimate is 504.98 KRW, implying the stock looks roughly 10.0% fairly valued today. The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, PeopleBio Inc generated revenue of 3.7B KRW at a net margin of -94.7%. Net debt stands at 7.3B KRW. Fundamentals as of Aug 13, 2026

Our scenario range runs from 376.85 KRW (bear case) to 753.70 KRW (bull case); at 561.00 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -10%, 304840 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
NCAV (Graham) 376.89 KRW 505.03 KRW 753.78 KRW 50
All 1 models by family
Asset-Based
NCAV (Graham) 376.89 KRW 505.03 KRW 753.78 KRW 50

Notify me when 304840 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 3.7B KRW
Revenue growth (YoY) +422%
Net margin -94.7%
Return on equity -10,161%
Free cash flow −5.5B KRW FY2025
Operating margin -227%
More key figures
Net debt 7.3B KRW FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 22/100

Of which business quality 25 · Market factors (momentum, volatility) 10

Profitability 0
Margins and returns on capital today
Quality Growth 28
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 47
Balance sheet, leverage, solvency risk
Investment 46
Disciplined investing over empire-building
Low Volatility 35
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 44
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

PeopleBio, Inc., a biotech company, engages in developing diagnostics for protein misfolding diseases worldwide. Its Multimer Detection System technology uses capturing antibodies and epitope-overlapping detection antibodies for the detection of oligomers or multimers from monomers in protein-misfolding diseases.

Full company description

PeopleBio, Inc., a biotech company, engages in developing diagnostics for protein misfolding diseases worldwide. Its Multimer Detection System technology uses capturing antibodies and epitope-overlapping detection antibodies for the detection of oligomers or multimers from monomers in protein-misfolding diseases. The company has strategic collaborations with Seoul National University Bundang Hospital, Etablissement Français du Sang, ADNI Private Partner Scientific Board, Eisai Co., Ltd., Macrogen Corp., ZheJiang Dian Diagnostics Co., Ltd., and LabGenomics, Inc. PeopleBio, Inc. was founded in 2002 and is based in Seongnam, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

PeopleBio Inc reported revenue of 2.9B KRW in FY2025 versus 577M KRW in FY2021, a compound +49.1%/yr. Reported net income was −15.7B KRW in FY2025.

Growth Quality 29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
2.9B KRW
Latest YoY
−23.6%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−13.8%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+41.2%
Avg. growth/yr (7Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+77.5%
Revenue +49.1%/yr
FY21 577M KRW
FY22 4.4B KRW
FY23 4.5B KRW
FY24 3.7B KRW
FY25 2.9B KRW
Net income
FY21 −4.7B KRW
FY22 −14.3B KRW
FY23 −16.0B KRW
FY24 −10.9B KRW
FY25 −15.7B KRW

Watch 304840: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "PeopleBio Inc Fair Value". https://www.fairvalue-calculator.com/stock/304840

Peer Group

Health Care · 2315 stocks

How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)

Quality Score 25 · Bottom 25%
Fair Value upside −10% · Above median
Return on assets -11% · Bottom 25%
Net margin (TTM) -95% · Bottom 25%
Revenue growth 422% · Top 25%

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE20 · sector 0
FUTURE100 · sector 21
PAST0 · sector 13
HEALTH100 · sector 96
DIVIDEND0 · sector 32

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
InBody Co 041830 67,400 KRW 49,984 KRW -26%
i-SENS, Inc 099190 18,480 KRW 8,168 KRW -56%
Value Added Technology Co 043150 20,950 KRW 60,242 KRW +188%
Mediana Co 041920 10,070 KRW 6,289 KRW -38%
Meta Biomed Co 059210 3,980 KRW 9,268 KRW +133%
Sewoon Medical Co 100700 2,300 KRW 6,054 KRW +163%
MEKICS CO., Ltd 058110 1,642 KRW 1,581 KRW -4%
CU Medical Systems, Inc 115480 2,195 KRW 1,134 KRW -48%
Novartis AG NVSN 2,742 MXN 1,952 MXN -29%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,944 ₹989.50 -49%

Compare PeopleBio Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Evidence & backtest 34 years, survivorship-adjusted Financial calculators DCF, Graham, PEG and more

Frequently asked questions

Is PeopleBio Inc (304840) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 504.98 KRW versus the last price from Jul 31, 2026 of 561.00 KRW, about −10% (fairly valued).
What is the fair value of 304840?
Our model-based fair value for PeopleBio Inc is 504.98 KRW (as of Aug 13, 2026), built from audited fundamentals. Last price (from Jul 31, 2026): 561.00 KRW.
What is the quality score of 304840?
PeopleBio Inc has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of PeopleBio Inc (304840)?
PeopleBio Inc reported trailing-twelve-month revenue of about 3.7B KRW (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 304840?
The net profit margin of PeopleBio Inc is about -94.7%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track PeopleBio Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.